Home » ISPOR November 2018 Abstracts » Making Sense From Anti-Sense: Lessons In Translating Expedited Regulatory Approval Into Reimbursement And Commercial Success

× Share this Article

Making Sense From Anti-Sense: Lessons In Translating Expedited Regulatory Approval Into Reimbursement And Commercial Success

October 4, 2018 Danielle Twigg

Educational poster presented at ISPOR Meeting, Barcelona, November 2018

A Comparison Of P&R Requirements For Orphan Drugs In 25 Markets

How Classification Of Cell And Gene Therapies As Drugs, Devices Or Procedures Could Have Significant Implications

Most Recent Articles

Treatment Disruption Among Patients With Parkinson’s Disease With Psychosis Enrolled In US Centers For Medicare Services

The Rise Of The Non-Submission – A Worrying Trend For UK Patient Access With ‘Brexit’ Approaching

The Impact Of Landmark Response On Overall Survival: Implications For The Economic Evaluation Of Immune-Therapy (I-O) Treatment

Spanish Therapeutic Positioning Reports: 6-Year Update – Increasing In Frequency But Not Relevance?

Pricing And Reimbursement Reforms In Spain – A Systematic Analysis Of National Pricing Decisions By The CIPM

Right To Breathe, Right To Choose?

Medicinrådet And The New Hospital Drug Appraisal Process In Denmark – The Story So Far

How Much Is Your Life Worth? Defining What The Willingness To Pay For A QALY Is and Should Be

Exploring The Impact Of Radiographic Progressive Disease And First Subsequent Therapy On Health State Utility Values

Danish Medicine Council Process Of Assessing New Hospital Medicines – First Year Of Implementation

Could ERG Preferences For Different Overall Survival Extrapolation Methodologies Drive Different Nice Appraisal Outcomes?

A Review Of Recent Appraisals From The Institute For Clinical And Economic Review: How Important Is The ICER?

A Cost Minimisation Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS)

A Budget Impact Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS) In The UK

Are Nice And The SMC Diverging In Their Assessment Of Oncology Drugs?

Pan-European HTA – Where We Have Been, Where We Are Going?

Payer Archetyping – Expanding Horizons

Less Haste, More Speed? Do European Accelerated Authorisations Translate Into Early Reimbursement And Patient Access?

A Comparison Of P&R Requirements For Orphan Drugs In 25 Markets

How Classification Of Cell And Gene Therapies As Drugs, Devices Or Procedures Could Have Significant Implications